Related Experiment Videos
Differentiation antigens in fetal human pancreas. Reexpression in cancer
Insights
Researchers developed a specific antiserum targeting fetal pancreatic antigens. This antiserum shows promise for detecting pancreatic adenocarcinomas and understanding oncodevelopmental antigens.
Area of Science:
- Immunology
- Developmental Biology
- Oncology
Background:
- Pancreatic cancer diagnosis often relies on late-stage detection.
- Identifying specific biomarkers for early detection and targeted therapy is crucial.
Purpose of the Study:
- To develop and characterize a novel antiserum against fetal pancreatic antigens.
- To evaluate the antiserum's specificity for pancreatic tissues and tumors.
Main Methods:
- Generation of polyclonal antiserum against human fetal pancreatic extracts.
- Immunohistochemical staining of fetal and adult pancreatic tissues, as well as various tumors.
- Absorption of antiserum with adult tissues to enhance specificity.
- Immunoblot assay to identify antigen molecular weights.
Main Results:
- The antiserum specifically recognized cytoplasmic antigens in fetal pancreatic acini (3-5 months gestation).
- Staining intensity decreased with gestational age, becoming negative in adults.
- The antiserum reacted strongly with 18/18 pancreatic adenocarcinomas and adjacent pancreatic acini.
- No reactivity was observed in other primary tumor types; mild reactivity seen in some chronic pancreatitis cases.
- Immunoblotting identified two main antigens (~60 kDa and ~110 kDa) in fetal pancreas and tumors.
Conclusions:
- The developed antiserum identifies a novel group of oncodevelopmental antigens with high pancreatic organ specificity.
- These antigens represent potential biomarkers for pancreatic cancer detection.
- The findings support the utility of this antiserum in cancer research and diagnostics.
Abstract:
An antiserum was raised against pancreatic extracts obtained from human fetuses under 5 months of gestational age. After absorption with adult tissues, this antiserum specifically recognized antigens located in the cytoplasm of fetal pancreatic acini. All of the examined pancreatic tissues, ranging from 3 to 5 months of gestational age, showed a strong positive reaction of most of the acinar cells. The number of stained acini and the staining intensity gradually decreased from 5 months onwards and by the 7th-8th month only a few cells remained positive. Adult pancreas was completely negative as were a variety of normal adult and fetal tissues. This antiserum also reacted with tumor structures in 18/18 pancreatic adenocarcinomas as well as with pancreatic acini in the vicinity of tumor. Primary carcinomas of the liver, large bowel, stomach, breast, urinary bladder, lung and other localizations did not react with this antiserum. In some cases of chronic pancreatitis (3/12) a reaction was observed in a few acinar cells. Immunoblot assay after polyacrylamide electrophoresis revealed, in both fetuses and tumors, two main antigens of approximately 60 kDa and 110 kDa relative molecular weight. Several minor components were also observed. These results suggest that our polyclonal antiserum defines a new group of oncodevelopmental antigens with high organ specificity.